Search

Your search keyword '"Kwan R"' showing total 366 results

Search Constraints

Start Over You searched for: Author "Kwan R" Remove constraint Author: "Kwan R"
366 results on '"Kwan R"'

Search Results

1. Rote learning: a necessary evil

5. A Web-Based Environment to Improve Teaching and Learning of Computer Programming in Distance Education

7. Population Pharmacokinetics for Oral Paclitaxel in Patients with Advanced/Metastatic Solid Tumors.

8. Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.

9. The liver contains distinct interconnected networks of CX3CR1+ macrophages, XCR1+ type 1 and CD301a+ type 2 conventional dendritic cells embedded within portal tracts

10. Abstract P1-16-05: Oraxol + Encequidar (OPac+E) vs IV paclitaxel (IVPac) in the treatment of patients with metastatic breast cancer (mBC) (Study KX-ORAX-001): Subgroup survival analysis of patients with hepatic dysfunction

11. Insomnia Severity Index--Hausa Version

13. 546P Phase I study with expansion cohorts to assess the safety, tolerability, and activity of oral paclitaxel (oPac) + encequidar (E) in combination with pembrolizumab (Pem) in subjects with advanced solid malignancies

15. Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.

16. Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1-infected patients

17. Targeted Genotyping Identifies Susceptibility Locus in Brain-derived Neurotrophic Factor Gene for Chronic Postsurgical Pain

18. Abstract PS13-06: Lower rates of neuropathy with oral paclitaxel and encequidar (oPac+E) compared to IV paclitaxel (IVPac) in treatment of metastatic breast cancer (mBC): Study KX-ORAX-001

19. Abstract PD1-08: Oral paclitaxel and encequidar (oPac+E) versus IV paclitaxel (IVPac) in the treatment of metastatic breast cancer (mBC) patients (study KX-ORAX-001): Progression free survival (PFS) and overall survival (OS) updates

20. Abstract PS13-11: Oral paclitaxel and encequidar (oPac+E) in the treatment of metastatic breast cancer (mBC): Management of gastrointestinal adverse events (GI AE). Study KX-ORAX-001

27. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

28. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial

34. A simplified 10-step Tai-chi programme to enable people with dementia to improve their motor performance: a feasibility study

35. Methodology to Assess Clinical Liver Safety Data

36. Satellite delivery of B-ISDN services

37. Technical and economic feasibility of integrated video service by satellite

38. Technology requirements for mesh VSAT applications

40. Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

41. Advanced communications payload for mobile applications

43. A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data

46. Effect of Predictive Performance of a Biomarker for the Sample Size of Targeted Designs for Randomized Clinical Trials

47. A Shrinkage Approach to Gene-Set Analysis

48. An open-label, randomized cross-over bioavailability study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours

49. Analyzing Two-Dimensional Gel Images

50. Ruggedness Study of HPLC Peptide Mapping for the Identity of a Drug Compound: A Chemometrics Approach

Catalog

Books, media, physical & digital resources